Erratum Regarding “KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update” (Am J Kidney Dis. 2012;60[5]:850-886)

American Journal of Kidney Diseases

In the special section entitled “KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update” that appeared in the November 2012 issue of AJKD (Nelson, Tuttle, Bilous, et el; volume 60, issue 5, pages 850-886), there was a typographical error affecting meaning. In particular, on page 874, in the first sentence under the heading “Newer Agents that Target the RAS”, the first sentence referred to “microalbuminuria” when it should have used the term “macroalbuminuria”. The corrected sentence reads in full as follows: “One 6-month phase 2 study of Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) reported a further reduction of albuminuria with the addition of the direct renin inhibitor aliskiren to losartan in patients with type 2 diabetes and macroalbuminuria.”